Claudin 18.2 Is Not a Promising Biomarker for Targeted Immunotherapy in Prostatic Cancers.

Baek J, Shim YR, Gu MJ

DOI: 10.21873/invivo.13884
Published: 2025 Mar-Apr
Container: In vivo (Athens, Greece)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.21873/invivo.13884,
  title = {Claudin 18.2 Is Not a Promising Biomarker for Targeted Immunotherapy in Prostatic Cancers.},
  author = {Baek J and Shim YR and Gu MJ},
  year = {2025},
  journal = {In vivo (Athens, Greece)},
  doi = {10.21873/invivo.13884},
  url = {https://doi.org/10.21873/invivo.13884}
}

RIS

TY  - JOUR
TI  - Claudin 18.2 Is Not a Promising Biomarker for Targeted Immunotherapy in Prostatic Cancers.
AU  - Baek J
AU  - Shim YR
AU  - Gu MJ
PY  - 2025
JO  - In vivo (Athens, Greece)
DO  - 10.21873/invivo.13884
UR  - https://doi.org/10.21873/invivo.13884
ER  -

APA

J, B., YR, S., & MJ, G. (2025). Claudin 18.2 Is Not a Promising Biomarker for Targeted Immunotherapy in Prostatic Cancers.. In vivo (Athens, Greece). https://doi.org/10.21873/invivo.13884

Source records

pubmed · retrieved 2026-09-27T08:11:06.744Z